Pharmaceutical composition of s-ketamine hydrochloride

ABSTRACT

The present invention is directed to an aqueous formulation of S-ketamine hydrochloride, preferably for nasal administration, wherein the formulation does not contain an antimicrobial preservative.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U. S. Provisional Application61/791,237, filed on Mar. 15, 2013, which is incorporated by referenceherein in its entirety.

FIELD OF THE INVENTION

The present invention is directed to an aqueous formulation ofS-ketamine hydrochloride, preferably for nasal administration, whereinthe formulation does not contain an antimicrobial preservative.

BACKGROUND OF THE INVENTION

Ketamine (a racemic mixture of the corresponding S- and R-enantiomers)is an NMDA receptor antagonist, with a wide range of effects in humans,including analgesia, anesthesia, hallucinations, dissociative effects,elevated blood pressure and bronchodilation. Ketamine is primarily usedfor the induction and maintenance of general anesthesia. Other usesinclude sedation in intensive care, analgesia (particularly in emergencymedicine and treatment of bronchospasms. Ketamine has also been shown tobe efficacious in the treatment of depression (particularly in those whohave not responded to current anti-depressant treatment). In patientswith major depressive disorders, ketamine has additionally been shown toproduce a rapid antidepressant effect, acting within hours.

The S-ketamine enantiomer (or S-(+)-ketamine or esketamine) has higherpotency or affinity for the NMDA receptor and thus potentially allowingfor lower effective dosages; and is available for medical use,administered either IV (intravenously) or IM (intramuscularly), underthe brand name KETANEST S.

In the formulation of a pharmaceutical compositing, the stability of theactive ingredient is a primary concern. In general, drug substances areless stable in aqueous media than solid dosage forms, and it isimportant to properly stabilize and preserve liquid aqueous formulationssuch as solutions, suspensions, and emulsions. Acid-base reactions, acidor base catalysis, oxidation, and reduction can occur in these products.These reactions can arise from drug substance-excipient interactions,excipient-excipient interactions or container-product interactions.Particularly for pH sensitive compounds, these interactions may alterthe pH and may decrease solubility and potentially cause precipitation.

Oxidative labile drug substances or vitamins, essential oils, and almostall fats and oils can be oxidized by auto-oxidation. Such reactions canbe initiated by heat, light, peroxides, or other labile compounds orheavy metals such as copper or iron.

The effect of trace metals can be minimized by using chelating agentssuch as EDTA. Antioxidants may retard or delay oxidation by rapidlyreacting with free radicals as they are formed (quenching). Commonantioxidants include propyl, octyl and dodecylesters of gallic acid,butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), ascorbicacid, sodium ascorbate, monothioglycerol, potassium or sodiummetabisulfite, propionic acid, propyl gallate, sodium bisulfite, sodiumsulfite, and the tocopherols or vitamin E.

In addition to stabilization of pharmaceutical preparations againstchemical and physical degradation, liquid and semisolid preparations,particularly multiple dosed preparations, must usually be protectedagainst microbial contamination. In contrast to solid preparations,aqueous solutions, syrups, emulsions, and suspensions often provideexcellent growth media for microorganisms such as molds, yeast, andbacteria (e.g. Pseudomonas Aeruginosa, E. Coli, Salmonella spp.,Staphylococcus aureus, Candida albicans, Aspergillus niger).Contamination by these microorganisms may occur during manufacturing orwhen a dose is taken from a multiple dosed formulation. Growth of themicroorganisms occurs when a sufficient amount of water is present inthe formulation.

Ophthalmic and injectable preparations are typically sterilized byautoclaving or filtration. However, many of them require the presence ofan antimicrobial preservative to maintain aseptic conditions throughouttheir stated shelf life, specifically for multiple dosed preparations.

When a preservative is required, its selection is based upon severalconsiderations, in particular the site of use whether internal, externalor ophthalmic (for further details it can be referred to e.g. Remington,The Science and Practice of Pharmacy, 21^(st) edition, LippincottWilliams & Wilkins, 2005). Many liquid formulations for oraladministration, particularly multiple dosed formulations, containparabens as preservatives, e.g. methyl paraben(methyl-4-hydroxybenzoate)and propyl paraben(propyl-4-hydroxybenzoate). For example, in theFederal Republic of Germany liquid oral formulations containing parabensare commercialized under the trademarks: ben-u-ron®;Cetirizin-ratiopharm®; Pipamperon HEXAL®; Sedotussin®; TALOXA®; Truxal®;XUSAL®; talvosilen®; and Timonil®. Other commercialized liquidformulations contain sorbic acid or its potassium salt as preservative,e.g. ibuprofen liquid formulations and morphine liquid formulations.

Because of the number of excipients and additives in these preparations,it is recommended all the ingredients be listed on the container toreduce the risks that confront hypersensitive patients when theseproducts are administered.

The preservatives benzalkonium chloride and potassium sorbate are alsowidely used e.g. in nasal drops and sprays. Recently, side effectsresulting from mucosal damage caused by benzalkonium chloride andpotassium sorbate were reported (cf. C. Y. Ho et al., Am J Rhinol. 2008,22(2), 125-9). As far as hypersensitivity reactions of preservatives intopical ophthalmic therapies are concerned, quaternary ammoniums(benzalkonium chloride) are commonly associated with irritant toxicreactions whereas the organomercurials (thimerosal) and the alcohols(chlorobutanol) have high associations, respectively, with allergicresponses (cf. J. Hong et al., Curr Opin Allergy Clin Immunol. 2009,9(5), 447-53). Parabens have been implicated in numerous cases ofcontact sensitivity associated with cutaneous exposure (cf. M. G. Soniet al., Food Chem Toxicol. 2001, 39(6), 513-32) and have been reportedto exert a weak estrogenic activity (cf. S. Oishi, Food Chem Toxicol.2002, 40(12), 1807-13 and M. G. Soni et al., Food Chem Toxicol. 2005,43(7), 985-015).

Due to these undesired side effects of known preservatives, it isdesirable to provide aqueous pharmaceutical compositions (for example,for nasal administration) that exhibit a sufficient shelf life and inuse stability in the absence of preservatives or at least in thepresence of comparatively low quantities thereof.

SUMMARY OF THE INVENTION

The present invention is directed to a pharmaceutical composition ofS-ketamine hydrochloride, comprising S-ketamine hydrochloride and water;wherein the pharmaceutical composition does not contain an antimicrobialpreservative.

In an embodiment, the present invention is directed to a pharmaceuticalcomposition of S-ketamine hydrochloride; wherein the formulation doesnot contain an antimicrobial preservative; and wherein thepharmaceutical composition is formulated for nasal administration.

The present invention is further directed to a pharmaceuticalcomposition of S-ketamine hydrochloride; wherein the formulation doesnot contain an antimicrobial preservative; and wherein thepharmaceutical composition further comprises a penetration enhancer,preferably TUDCA.

In another embodiment, the present invention is directed to apharmaceutical composition of S-ketamine hydrochloride; wherein theformulation does not contain an antimicrobial preservative; and whereinthe pharmaceutical composition further comprises TUDCA; wherein theTUDCA is present in a concentration in the range of from about 1.0 mg/mLto about 25 mg/mL.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 illustrated Esketamine Plasma Levels dosing Formulations 5-Athrough 5-D at 10 μL/rat.

FIG. 2 illustrated Esketamine Plasma Levels dosing Formulations 5-A and5-C at 25 μL/rat.

FIG. 3 illustrated Esketamine Plasma Levels dosing Formulations 5-A andReference Formulation 5-E at 25 μL/rat.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to pharmaceutical composition ofS-ketamine, wherein the pharmaceutical composition does not contain anantimicrobial preservative.

The pharmaceutical compositions of the present invention are based onthe unexpected finding that S-ketamine hydrochloride exhibitspreservative properties. Thus, when formulating pharmaceuticalcompositions of S-ketamine hydrochloride, particularly aqueous liquidcompositions, preservatives can be completely omitted while stillachieving desired shelf life. Further, although the pharmaceuticalcompositions of S-ketamine hydrochloride of the present invention do notcontain an antibacterial preservative, said compositions do not need tomanufactured under aseptic conditions and/or do not need to besterilized after production.

Additionally, wherein the pharmaceutical compositions of the presentinvention are formulated for nasal administration, the absence ofpreservatives results in the elimination of adverse effects associatedwith said preservatives, including for example, irritation or damage ofthe mucosal membrane.

As used herein, unless otherwise noted, the terms “S-ketamine”,“S-ketamine hydrochloride” and “esketamine” shall mean the(S)-enantiomer of ketamine, as its corresponding hydrochloride salt, acompound of formula (I)

also known as (S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanonehydrochloride.

As used herein, the term “composition” is intended to encompass aproduct comprising the specified ingredients in the specified amounts,as well as any product which results, directly or indirectly, fromcombinations of the specified ingredients in the specified amounts.

The term “pharmaceutical composition” includes any pharmaceuticalpreparation or formulation that is customized for being administered toa human being or animal. Preferably, the composition contains one ormore physiologically acceptable carriers and/or excipients. Preferably,the pharmaceutical compositions of the present invention contain water.

To prepare a pharmaceutical composition of the present invention,S-ketamine hydrochloride as the active ingredient is intimately admixedwith a pharmaceutical carrier, preferably water, according toconventional pharmaceutical compounding techniques, which carrier maytake a wide variety of forms depending of the form of preparationdesired for administration. Suitable pharmaceutically acceptablecarriers are well known in the art. Descriptions of some of thesepharmaceutically acceptable carriers may be found in The Handbook ofPharmaceutical Excipients, published by the American PharmaceuticalAssociation and the Pharmaceutical Society of Great Britain.

Methods of formulating pharmaceutical compositions have been describedin numerous publications such as Pharmaceutical Dosage Forms: Tablets,Second Edition, Revised and Expanded, Volumes 1-3, edited by Liebermanet al; Pharmaceutical Dosage Forms: Parenteral Medications, Volumes 1-2,edited by Avis et al; and Pharmaceutical Dosage Forms: Disperse Systems,Volumes 1-2, edited by Lieberman et al; published by Marcel Dekker, Inc.

In an embodiment, the present invention is directed to an aqueousformulation of S-ketamine, comprising water and S-ketamine; wherein theS-ketamine is present in an amount in the range of from about 100 mg/mLto about 250 mg/mL, or any amount or range therein, based on the totalvolume of the pharmaceutical composition. Preferably, the S-ketamine ispresent in an amount in the range of from about 150 mg/ml to about 200mg/mL, or any amount or range therein. More preferably, the S-ketamineis present in an amount in the range of from about 150 mg/mL to about175 mg/mL, or any amount or range therein. More preferably, theS-Ketamine is present in an amount in the range of from about 160 mg/mLto about 163 mg/mL, for example, in an amount of about 161.4 mg/mL.

In an embodiment, the present invention is directed to an aqueousformulation of S-ketamine, comprising water and S-ketamine; wherein theS-ketamine is present in an amount in the range of from about eq. 100mg/mL to about eq. 250 mg/mL, or any amount or range therein, based onthe total volume of the pharmaceutical composition. Preferably, theS-ketamine is present in an amount in the range of from about eq. 125mg/ml to about eq. 180 mg/mL, or any amount or range therein. Morepreferably, the S-ketamine is present in an amount in the range of fromabout eq. 140 mg/mL to about eq. 160 mg/mL, or any amount or rangetherein, for example, in an amount of about eq. 140 mg/mL.

The pharmaceutical compositions according to the invention arepreferably an aqueous formulation. As used herein, unless otherwisenoted, the term “aqueous” shall mean that the primary liquid componentof the formulation is water. Preferably, water constitutes greater thanabout 80 wt % of the liquid component of the pharmaceutical composition,more preferably greater than about 90 wt %, more preferably greater thanabout 95 wt %, more preferably about 98 wt %.

In an embodiment of the present invention, the water content of thecomposition is within the range of 85±14 wt.-%, more preferably 85±12wt.-%, still more preferably 85±10 wt.-%, most preferably 85±7.5 wt.-%and in particular 85±5 wt.-%, based on the total weight of thecomposition.

In another embodiment of the present invention, the water content of thecomposition is within the range of 90±14 wt.-%, more preferably 90±12wt.-%, still more preferably 90±10 wt.-%, most preferably 80±7.5 wt.-%and in particular 90±5 wt.-%, based on the total weight of thecomposition. In another embodiment of the present invention, the watercontent of the composition is within the range of 95±4.75 wt.-%, morepreferably 95±4.5 wt.-%, still more preferably 95±4 wt.-%, yet morepreferably 95±3.5 wt.-%, most preferably 95±3 wt.-% and in particular95±2.5 wt.-%, based on the total weight of the composition.

In another embodiment of the present invention, the water content of thecomposition is within the range of from 75 to 99.99 wt.-%, morepreferably 80 to 99.98 wt.-%, still more preferably 85 to 99.95 wt.-%,yet more preferably 90 to 99.9 wt.-%, most preferably 95 to 99.7 wt.-%and in particular 96.5 to 99.5 wt.-%, based on the total weight of thecomposition.

In another embodiment, the pharmaceutical compositions of the presentinvention further comprises one or more buffers and/or buffer systems(i.e. conjugate acid-base-pairs).

As used herein, the term “buffer” shall mean any solid or liquidcomposition (preferably an aqueous, liquid composition) which when addedto an aqueous formulation adjusts the pH of said formulation. Oneskilled in the art will recognize that a buffer may adjust the pH of theaqueous formulation in any direction (toward more acidic, more basic ormore neutral pH). Preferably, the buffer is pharmaceutically acceptable.

Suitably examples of buffers which may be used in the aqueousformulations of the present invention include, but are not limited tocitric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate,acetic acid, boric acid, sodium borate, succinic acid, tartaric acid,malic acid, lactic acid, furmaric acid, and the like. Preferably, thebuffer or buffer system is selected from the group consisting of NaOH,citric acid, sodium dihydrogen phosphate and disodium hydrogenphosphate.

In an embodiment, the buffer is selected to adjust the pH of theS-ketamine hydrochloride pharmaceutical compositions of the presentinvention (e.g. the aqueous formulations described herein) into a pH inthe range of from about pH 3.5 to about pH 6.5, or any amount or rangetherein. Preferably, the buffer is selected to adjust the pH of theS-ketamine hydrochloride compositions of the present invention to aboutin the range of from about pH 4.0 to about pH 5.5, or any amount orrange therein, more preferably, in the range of from about pH 4.5 toabout pH 5.0, or any amount or range therein.

Preferably, the concentration of the buffer and buffer system,respectively, preferably NaOH, is adjusted to provide a sufficientbuffer capacity.

In an embodiment, the present invention is directed to a pharmaceuticalcomposition comprising S-ketamine hydrochloride, water, and a buffer orbuffer system, preferably NaOH; wherein the buffer or buffer system ispresent in an amount sufficient to yield a formulation with a pH in therange of from about pH 4.0 to about pH 6.0, or any amount or rangetherein.

The pharmaceutical compositions of the present invention do not containa preservative.

As used herein, unless otherwise noted, the terms “antimicrobialpreservative” and “preservative” preferably refer to any substance thatis usually added to pharmaceutical compositions in order to preservethem against microbial degradation or microbial growth. In this regard,microbial growth typically plays an essential role, i.e. thepreservative serves the main purpose of avoiding microbialcontamination. As a side aspect, it may also be desirable to avoid anyeffect of the microbes on the active ingredients and excipients,respectively, i.e. to avoid microbial degradation.

Representative examples of preservatives include, but are not limitedto, benzalkonium chloride, benzethonium chloride, benzoic acid, sodiumbenzoate, benzyl alcohol, bronopol, cetrimide, cetylpyridinium chloride,chlorhexidine, chlorbutanol, chlorocresol, chloroxylenol, cresol, ethylalcohol, glycerin, hexetidine, imidurea, phenol, phenoxyethanol,phenylethyl alcohol, phenylmercuric nitrate, propylene glycol, sodiumpropionate, thimerosal, methyl paraben, ethyl paraben, propyl paraben,butyl paraben, isobutyl paraben, benzyl paraben, sorbic acid, andpotassium sorbate.

The complete absence of preservatives in the pharmaceutical compositionsof the present invention is preferred when the content of S-ketaminehydrochloride is sufficiently high so that due to its preservativeproperty the desired shelf life or in use stability can be achieved bythe presence of the drug itself. Preferably, under these circumstancesthe concentration of S-ketamine hydrochloride is at least eq. 120 mg/mL,preferably in the range of from about eq, 120mg/mL to about eq. 175mg/ml, or any amount or range therein, more preferably in an amount inthe range of from about eq. 125 mg/mL to about eq. 150 mg/mL, or anyamount or range therein, for example at about eq. 126 mg/mL or at abouteq. 140 mg/mL.

As used herein, the terms “penetration agent”, “penetration enhancer”,and “penetrant” refer to any substance that increases or facilitatesabsorption and/or bioavailability of the active ingredient (e.g.S-ketamine hydrochloride) of a pharmaceutical composition. Preferably,the penetration agents increases or facilitates absorption and/orbioavailability of the active ingredient (e.g. S-ketamine hydrochloride)of a pharmaceutical composition, following nasal administration (i.e.increases or facilitates absorption and/or bioavailability of the activeingredient through the mucosal membrane).

Suitable examples include, but are not limited to tetradecyl maltoside,sodium glycocholate, tauroursodeoxycholic acid (TUDCA), lecithines, andthe like; and chitosan (and salts), and surface active ingredients suchas benzalkonium chloride, sodium dodecyl sulfate, sodium docusate,polysorbates, laureth-9, oxtoxynol, sodium deoxycholate, polyarginine,and the like. Preferably, the penetration agent is tauroursodeoxycholicacid (TUDCA).

The penetration agent may work via any mechanism, including for exampleby increasing the membrane fluidity, creating transient hydrophilicpores in the epithelial cells, decreasing the viscosity of the mucuslayer or opening up tight junctions. Some penetration agents (forexample bile salts and fusidic acid derivatives) may also inhibit theenzymatic activity in the membrane, thereby improving bioavailability ofthe active ingredient.

Preferably, the penetration agent is selected to meet one or more, morepreferably all, of the following general requirements:

(a) It is effective at increasing absorption (preferably nasalabsorption) of the active ingredient, preferably in a temporary and/orreversible manner;

(b) It is pharmacologically inert;

(c) It is non-allergic, non-toxic and/or non-irritating;

(d) It is highly potent (effective in small amounts);

(e) It is compatible with the other components of the pharmaceuticalcomposition;

(f) It is odorless, colorless and/or tasteless;

(g) It is accepted by regulatory agencies; and

(h) It is inexpensive and available in high purity.

In an embodiment of the present invention, the penetration agent isselected to increase penetration (absorption and/or bioavailability ofthe S-ketamine hydrochloride) without nasal irritation. In anotherembodiment of the present invention, the penetration agent is selectedto improve absorption and/or biovailability of the S-ketaminehydrochloride; and further selected to enhance uniform dosing efficacy.

In an embodiment, the present invention is directed to a pharmaceuticalcomposition comprising S-ketamine and water; herein the pharmaceuticalcomposition does not contain an antimicrobial preservative; and whereinthe pharmaceutical compositions further contains a penetration enhancer,preferably TUDCA.

In another embodiment, the present invention is directed to apharmaceutical composition comprising S-ketamine and water; herein thepharmaceutical composition does not contain an antimicrobialpreservative; and wherein the pharmaceutical compositions furthercontains tauroursodeoxycholic acid (TUDCA); wherein the TUDCA is presentin a concentration in the range of from about 1.0 mg/mL to about 25.0mg/mL, or any amount or range therein, preferably in a concentration inthe range of from about 2.5 mg/mL to about 15 mg/mL, or any amount orrange therein, preferably in a concentration in the range of from about5 mg/mL to about 10 mg/mL, or any amount or range therein. In anotherembodiment, the present invention is directed to pharmaceuticalcomposition wherein the TUDCA is present at a concentration of about 5mg/mL. In another embodiment, the present invention is directed topharmaceutical composition wherein the TUDCA is present at aconcentration of about 10 mg/mL.

The pharmaceutical compositions of the present invention may furthercontain one or more additional excipients for example, wetting agents,surfactant components, solubilizing agents, thickening agents, colorantagents, antioxidant components, and the like.

Examples of a suitable antioxidant component, if used, include, but arenot limited to one or more of the following: sulfites; ascorbic acid;ascorbates, such as sodium ascorbate, calcium ascorbate, or potassiumascorbate; ascorbyl palmitate; fumaric acid; ethylene diaminetetraacetic acid (EDTA) or its sodium or calcium salts; tocopherol;gallates, such as propyl gallate, octyl gallate, or dodecyl gallate;vitamin E; and mixtures thereof. The antioxidant component provides longterm stability to the liquid compositions. Addition of the antioxidantcomponent can help enhance and ensure the stability of the compositionsand renders the compositions stable even after six months at 40 ° C. Asuitable amount of the antioxidant component, if present, is about 0.01wt.-% to about 3 wt.-%, preferably about 0.05 wt.-% to about 2 wt.-%, ofthe total weight of the composition.

Solubilizing and emulsifying agents can be included to facilitate moreuniform dispersion of the active ingredient or other excipient that isnot generally soluble in the liquid carrier. Examples of a suitableemulsifying agent, if used, include, but are not limited to, forexample, gelatin, cholesterol, acacia, tragacanth, pectin, methylcellulose, carbomer, and mixtures thereof. Examples of a suitablesolubilizing agent include polyethylene glycol, glycerin, D-mannitol,trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol,triethanolamine, sodium carbonate, sodium citrate, sodium salicylate,sodium acetate, and mixtures thereof.

Preferably, the solubilizing agent includes glycerin. The solubilizingor emulsifying agent is/are generally present in an amount sufficient todissolve or disperse the active ingredient, i.e. S-ketamine, in thecarrier. Typical amounts when a solubilizing or an emulsifier areincluded are from about 1 wt.-% to about 80 wt.-%, preferably about 20wt.-% to about 65 wt.-%, and more preferably about 25 wt.-% to about 55wt.-%, of the total weight of the composition.

A suitable isotonizing agent, if used, includes sodium chloride,glycerin, D-mannitol, D-sorbitol, glucose, and mixtures thereof. Asuitable amount of the isotonizing agent, when included, is typicallyabout 0.01 wt.-% to about 15 wt.-%, more preferably about 0.3 wt.-% toabout 4 wt.-%, and more preferably about 0.5 wt.-% to about 3 wt.-%, ofthe total weight of the composition.

A Suspending agent or viscosity increasing agent can be added to to thepharmaceutical compositions of the present invention, to for example,increase the residence time in the nose. Suitably examples include, butare not limited to, hydroxypropyl methylcellulose, sodium carmellose,microcrystalline cellulose, carbomer, pectin, sodium alginate, chitosansalts, gellan gum, poloxamer, polyvinyl pyrrolidone, xanthan gum, andthe like.

As used herein the term “shelf life” refers to the storage stability ofa closed container of the pharmaceutical composition.

Preferably, the pharmaceutical compositions according to the presentinvention exhibit antimicrobial robustness that complies with therequirements for nasal pharmaceutical compositions (for example, the Ph.Eur. requirements). Requirements for the following organisms:Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candidaalbicans, Aspergillus niger (for example, A. Brasiliensis, a nigervariety), and Micrococcus luteus (an in-house, J&J organism) are aslisted in Table 1, below.

TABLE 1 Bacterial & Fungal Requirements for Nasal CompositionsRequirement Std. 6 hrs 24 hrs 48 hrs 7 days 14 days 28 days BacteriaEur. A — — log 2 log 3 — NI/7 d Eur. B — — — — log 3 NI/14 d J&J — — — —log 3 NI/14 d U.S.P. — — — — >=2.0 NI/14 d J.P. — — — — >=2.0 NI/14 dFungi Eur. A — — — — log 2 NI/14 d Eur. B — — — — log 1 NI/14 d J.&J. —— — — log 2.0 NI/14 d U.S.P. — — — — NI/Init. NI/Init. J.P. — — — —NI/Init. NI/Init.

Preferably, antimicrobial robustness is achieved against one or more ofE. coli, S. aureus, Ps. Aeruginosa, S. spp., M. luteus and/or C.albicans.

Preferably, the pharmaceutical compositions of the present inventionexhibit a shelf-life under accelerated storage conditions of at least 1month, more preferably at least 2 months, still more preferably at least3 months, yet more preferably at least 4 months, most preferably atleast 5 months and in particular at least 6 months. Preferably, theshelf life is determined according to Ph. Eur., particularly asdescribed in the experimental section. Accelerated storage conditionspreferably mean 40° C./75% Relative Humidity (% RH).

Preferably, the pharmaceutical compositions of the present inventionexhibit a shelf-life under ambient conditions of at least 6 months, morepreferably at least 12 months, still more preferably at least 15 months,yet more preferably at least 18 months, most preferably at least 21months and in particular at least 24 months.

In an embodiment, the present invention is directed to a pharmaceuticalcomposition comprising: (a) S-ketamine hydrochloride 161.4 mg/mL; (b)NaOH q.s. ad pH 4.5; wherein the NaOH is preferably added to thepharmaceutical composition as a 1N solution; (c) purified water q.s. ad1000 μL; and wherein pharmaceutical compositions does not containantimicrobial preservative.

In another embodiment, the present invention is directed to apharmaceutical composition comprising: (a) S-ketamine hydrochloride @161.4 mg/mL; (b) NaOH q.s. ad pH 4.5; wherein the NaOH is preferablyadded to the pharmaceutical composition as a 1N solution; (c) purifiedwater q.s. ad 1000 μL; and (d) TUDCA @ 1.25 mg/mL; and whereinpharmaceutical compositions does not contain antimicrobial preservative.

In another embodiment, the present invention is directed to apharmaceutical composition comprising: (a) S-ketamine hydrochloride @161.4 mg/mL; (b) NaOH q.s. ad pH 4.5; wherein the NaOH is preferablyadded to the pharmaceutical composition as a 1N solution; (c) purifiedwater q.s. ad 1000 μL; and (d) TUDCA @ 2.5 mg/mL; and whereinpharmaceutical compositions does not contain antimicrobial preservative.

In another embodiment, the present invention is directed to apharmaceutical composition comprising: (a) S-ketamine hydrochloride @161.4 mg/mL; (b) NaOH q.s. ad pH 4.5; wherein the NaOH is preferablyadded to the pharmaceutical composition as a 1N solution; (c) purifiedwater q.s. ad 1000 μL; and (d) TUDCA @ 5 mg/mL; and whereinpharmaceutical compositions does not contain antimicrobial preservative.

In another embodiment, the present invention is directed to apharmaceutical composition comprising: (a) S-ketamine hydrochloride @161.4 mg/mL; (b) NaOH q.s. ad pH 4.5; wherein the NaOH is preferablyadded to the pharmaceutical composition as a 1N solution; (c) purifiedwater q.s. ad 1000 μL; and (d) TUDCA @ 10 mg/mL; and whereinpharmaceutical compositions does not contain antimicrobial preservative.

In another embodiment, the present invention is directed to apharmaceutical composition comprising: (a) S-ketamine hydrochloride @161.4 mg/mL; (b) NaOH q.s. ad pH 4.5; wherein the NaOH is preferablyadded to the pharmaceutical composition as a 1N solution; (c) purifiedwater q.s. ad 1000 μL; and (d) TUDCA @ 15 mg/mL; and whereinpharmaceutical compositions does not contain antimicrobial preservative.

In an embodiment, the pharmaceutical composition of the presentinvention is prepared by adding water to the S-ketamine hydrochloride;followed by addition of 1N NaOH_((aq)) to adjust the pH of the resultingmixture to the desired pH, preferably to a pH in the range of from aboutpH 3.5 to about pH 6.0, more preferably to about pH in the range of fromabout pH 4.0 to about pH 5.0, more preferably to about pH 4.5.

In a preferred embodiment, the pharmaceutical compositions of thepresent invention are ready to use, i.e. do not require particulartreatment steps such as dissolution in a solvent before they may beadministered to the patient.

A skilled person recognizes that the pharmaceutical compositions of thepresent invention may alternatively be commercialized as a precursor inform of a dry powder that is to be dissolved or dispersed in anappropriate amount of water prior to the first use.

A further aspect of the invention relates to a pharmaceutical dosageform comprising the pharmaceutical composition according to theinvention. All preferred embodiments that are described above inconnection with the composition according to the invention also apply tothe dosage form according to the invention.

In an embodiment, the dosage form according to the invention is adaptedfor nasal administration. Preferably, the dosage form according to theinvention is adapted for administration once every couple of days, onindividually determined days only; or once daily, twice daily, thricedaily, four times daily, five times daily, six times daily or even morefrequently; or clustered as between 2 and up to 8 consecutiveadministrations within a limited time period ranging from 1 to about 60minutes.

The present invention is further directed to methods for the treatmentof depression, preferably resistant depression or treatment refractorydepression, comprising administering to a subject in need thereof, atherapeutically effective amount of any of the pharmaceuticalcompositions a described herein. Preferably, the administration isnasal.

In an embodiment, the present invention is directed to a method for thetreatment of depression, preferably resistant depression or treatmentrefractory depression, comprising the nasal administration of thepharmaceutical composition according to the invention as described aboveor of the pharmaceutical dosage form according to the invention asdescribed above, to a subject in need thereof.

As used herein, the term “depression” shall be defined to include majordepressive disorder, unipolar depression, treatment-refractorydepression, resistant depression, anxious depression, bipolar depressionand dysthymia (also referred to as dysthymic disorder). Preferably, thedepression is major depressive disorder, unipolar depression,treatment-refractory depression, resistant depression, anxiousdepression or bipolar depression.

As used herein, the term “treatment-refractory or treatment-resistantdepression” and the abbreviation “TRD” shall be defined as majordepressive disorder that does not respond to adequate courses of atleast two antidepressants, preferably two or more antidepressants, morepreferably two to three, antidepressants.

As used herein, the term “bipolar depression” is intended to mean thedepression associated with, characteristic of or symptomatic of abipolar disorder. Thus, methods of treating bipolar depression of thepresent invention are directed to methods which treat the depressionand/or depressed phase of bipolar disorders.

One skilled in the art will recognize that the failure to respond to anadequate course of a given antidepressant may be determinedretrospectively or prospectively. In an embodiment, at least one of thefailures to respond to an adequate course of antidepressant isdetermined prospectively. In another embodiment, at least two of thefailures to respond to an adequate course of antidepressant aredetermined prospectively. In another embodiment, at least one of thefailures to respond to an adequate course of antidepressant isdetermined retrospectively. In another embodiment, at least two of thefailures to respond to an adequate course of antidepressant aredetermined retrospectively.

As used herein, unless otherwise noted, the terms “treating”,“treatment” and the like, shall include the management and care of asubject or patient (preferably mammal, more preferably human) for thepurpose of combating a disease, condition, or disorder and includes theadministration of a compound of the present invention to prevent theonset of the symptoms or complications, alleviate the symptoms orcomplications, or eliminate the disease, condition, or disorder.

The term “therapeutically effective amount” as used herein, means thatamount of active compound or pharmaceutical agent that elicits thebiological or medicinal response in a tissue system, animal or humanthat is being sought by a researcher, veterinarian, medical doctor orother clinician, which includes alleviation of the symptoms of thedisease or disorder being treated.

Optimal dosages to be administered may be readily determined by thoseskilled in the art, and will vary with the particular compound used, themode of administration, the strength of the preparation, the mode ofadministration, the number of consecutive administrations within alimited period of time (e.g. up to 60 minutes) and the advancement ofthe disease condition. In addition, factors associated with theparticular patient being treated, including patient age, weight, dietand time of administration, will result in the need to adjust dosages.

The term “subject” as used herein, refers to an animal, preferably amammal, most preferably a human, who has been the object of treatment,observation or experiment. Preferably, the subject has experiencedand/or exhibited at least one symptom of the disease or disorder to betreated and/or prevented.

To provide a more concise description, some of the quantitativeexpressions herein are recited as a range from about amount X to aboutamount Y. It is understood that wherein a range is recited, the range isnot limited to the recited upper and lower bounds, but rather includesthe full range from about amount X through about amount Y, or any amountor range therein.

To provide a more concise description, some of the quantitativeexpressions given herein are not qualified with the term “about”. It isunderstood that whether the term “about” is used explicitly or not,every quantity given herein is meant to refer to the actual given value,and it is also meant to refer to the approximation to such given valuethat would reasonably be inferred based on the ordinary skill in theart, including approximations due to the experimental and/or measurementconditions for such given value.

The following Examples are set forth to aid in the understanding of theinvention, and are not intended and should not be construed to limit inany way the invention set forth in the claims which follow thereafter.

EXAMPLE 1 Microbial Challenge Test for Nasal Spray PharmaceuticalComposition Containing S-ketamine Hydrochloride (eq. 140 mg/ml)

An aqueous formulation of S-ketamine hydrochloride referred to as“S-ketamine eq. 140 mg/ml below, was prepared by mixing S-ketaminehydrochloride (at a concentration of 161.4 mg/ml) in water and thenadding 1N NaOH_((aq)) to pH 5.0.

A challenge test was initiated to investigate whether the formulationcould prevent microorganisms from proliferating. The challenge testconsisted of challenging the formulation with a prescribed inoculum ofmicroorganisms. The inoculated formulation was then stored at roomtemperature and at specified time intervals a sample was withdrawn tocount the microorganisms in the sample.

As shown in Table 2 below, the challenge test results on S-ketamine eq.140 mg/ml pH 5.0 show that S-ketamine eq. 140mg/ml pH 5.0 reduced theoriginal spike (10⁵-10⁶ CFU/ml) of bacteria (i.e. Pseudomonasaeruginosa, Staphylococcus aureus, Escherichia coli and environmentalisolate Staphylococcus haemolyticus) and also of the yeast Candidaalbicans. S-ketamine eq. 140mg/ml pH 5.0 was not able to reduce theoriginal spike of Aspergillus brasiliensis to the same extent as for thebacteria and yeast, but no increase was observed after 28 days ofincubation at room temperature.

TABLE 2 Challenge Test S-ketamine eq. 140 mg/ml pH 5.0 (CFU/ml) ProductBlank at at 0 at 2 at 7 at 14 at 28 Organism 0 hours hours days daysdays days A. 1.50 × 10⁵ 1.90 × 10⁵ ND 4.80 × 5.80 × 2.65 × brasiliensis10⁴ 10⁴ 10⁴ C. albicans 1.15 × 10⁵ 6.50 × 10⁴ ND <5 <5 <5 P. 2.65 × 10⁵1.59 × 10⁴ <50 <5 <5 <5 aeruginosa S. aureus 1.90 × 10⁵ 1.70 × 10⁵ <50<5 <5 <5 E. coli 1.20 × 10⁵ 6.00 × 10⁴ <50 <5 <5 <5 S. 1.20 × 10⁵ 7.50 ×10⁴ <50 <5 <5 <5 haemolyticus ND: not determined

EXAMPLE 2 Microbial Challenge for Nasal Spray Pharmaceutical CompositionContaining S-ketamine Hydrochloride

Aqueous formulation of S-ketamine hydrochloride as listed in Table 3,below, were prepared by mixing S-ketamine hydrochloride (at the listedconcentrations) in water and then adding 1N NaOH_((aq)) to the listed pHlevels. Formulation F-5 additionally contained 10 mg/mL oftauroursodeoxycholic acid (TU DCA).

TABLE 3 Composition of edge of failure batches Formulation ConcentrationAPI(mg/ml) pH F-1 eq. 126 4.0 F-2 eq. 140 4.5 F-3 eq. 126 5.0 F-4 eq.126 4.5 F-5 eq. 140 4.5 * This formulation also contained 10 mg/mLTauroursodeoxycholic acid (TUDCA)Low Level A. brasiliensis Challenge

The formulations listed in Table 3, above were subjected to a low levelchallenge with A. brasiliensis to evaluate whether the formulationswould be able to reduce this lower spike, with results as shown in Table4, below. A spike of 10³ CFU/ml was chosen instead of 10⁵-10⁶ CFU/ml,which is the standard spike for a challenge test.

TABLE 4 Low Level Challenge with A. brasiliensis Product (CFU/ml)Formulation 0 hours 7 days 14 days 28 days F-1 4.45E+02 2.35E+022.15E+02 1.75E+02 F-2 3.80E+02 2.50E+02 2.00E+02 2.00E+02 F-3 5.50E+022.75E+02 2.65E+02 1.10E+02 F-4 3.85E+02 2.70E+02 2.60E+02 1.55E+02 F-54.10E+02 4.00E+02 3.15E+02 2.25E+02 Blank 4.75E+02 NA NA NA

The results, as listed in Table 3, above, show that in none of thetested formulation was an increase in Aspergillus brasiliensis observedafter 28 days of incubation, rather a minor and slow decrease wasobserved.

Full AET Challenge Test

The formulations listed in Table 3 were additionally subjected to a FullAET challenge, with results for the individual formulations are shown inTables 5-9, below. Additionally, Table 10 below, provides results for aFull AET challenge of a reference formulation containing 0.00 mg/mLS-ketamine hydrochloride, denatonium benzoate (to mimic the taste of theS-ketamine HCl formulation(s)), and adjusted to pH 5.21 with 1N NaOH.

TABLE 5 Full AET Challenge Test Formulation F-1: S-ketamine eq. 126mg/ml pH 4.0 (CFU/ml) Product Blank at at 2 at 7 at 14 at 28 Organism 0hrs at 0 hrs days days days days A. brasiliensis 1.55 × 10⁵ 2.15 × 10⁵ND 5.30 × 2.10 × 3.5 × 10⁴ 10⁴ 10³ C. albicans 1.05 × 10⁵ 1.15 × 10⁴ ND<5 <5 <5 P. aeruginosa 5.05 × 10⁵ 1.10 × 10⁴ <50 <5 <5 <5 S. aureus 6.00× 10⁵ 6.25 × 10⁵ <50 <5 <5 <5 E. coli 6.05 × 10⁵ 4.00 × 10⁴ <50 <5 <5 <5M. luteus 1.65 × 10⁵ 7.50 × 10⁴ <50 <5 <5 <5 ND: not determined

TABLE 6 Full AET Challenge Test Formulation F-2: S-ketamine eq. 140mg/ml pH 4.5 (CFU/ml) Product Blank at at 2 at 7 at 14 at 28 Organism 0hrs at 0 hrs days days days days A. brasiliensis 1.55 × 10⁵ 1.20 × 10⁵ND 1.65 × 1.00 × 2.0 × 10⁴ 10⁴ 10³ C. albicans 1.05 × 10⁵ 1.15 × 10⁴ ND<5 <5 <5 P. aeruginosa 5.05 × 10⁵ 7.55 × 10⁴ <50 <5 <5 <5 S. aureus 6.00× 10⁵ 5.70 × 10⁵ <50 <5 <5 <5 E. coli 6.05 × 10⁵ 2.80 × 10⁴ <50 <5 <5 <5M. luteus 1.65 × 10⁵ 1.70 × 10⁴ <50 <5 <5 <5 ND: not determined

TABLE 7 Full AET Challenge Test Formulation F-3: S-ketamine eq. 126mg/ml pH 5.0 (CFU/ml) Product Blank at at 2 at 7 at 14 at 28 Organism 0hrs at 0 hrs days days days days A. brasiliensis 1.55 × 10⁵ 1.90 × 10⁵ND 3.50 × 2.15 × 8.0 × 10⁴ 10⁴ 10³ C. albicans 1.05 × 10⁵ 1.60 × 10⁴ ND<5 <5 <5 P. aeruginosa 5.05 × 10⁵ 1.03 × 10⁴ <50 <5 <5 <5 S. aureus 6.00× 10⁵ 6.05 × 10⁵ <50 <5 <5 <5 E. coli 6.05 × 10⁵ 2.00 × 10⁴ <50 <5 <5 <5M. luteus 1.65 × 10⁵ 1.60 × 10⁴ <50 <5 <5 <5 ND: not determined

TABLE 8 Full AET Challenge Test Formulation F-4: S-ketamine eq. 126mg/ml pH 4.5 (CFU/ml) Product Blank at at 2 at 7 at 14 at 28 Organism 0hrs at 0 hrs days days days days A. brasiliensis 1.55 × 10⁵ 2.10 × 10⁵ND 5.30 × 2.10 × 5.5 × 10⁴ 10⁴ 10³ C. albicans 1.05 × 10⁵ 2.85 × 10⁴ ND<5 <5 <5 P. aeruginosa 5.05 × 10⁵ 8.35 × 10⁴ <50 <5 <5 <5 S. aureus 6.00× 10⁵ 7.60 × 10⁵ <50 <5 <5 <5 E. coli 6.05 × 10⁵ 4.80 × 10⁴ <50 <5 <5 <5M. luteus 1.65 × 10⁵ 7.00 × 10⁴ <50 <5 <5 <5 ND: not determined

TABLE 9 Full AET Challenge Test Formulation F-5: S-ketamine eq. 140mg/ml pH 4.5, TUDCA @ 10 mg/mL (CFU/ml) Product Blank at at 2 at 7 at 14at 28 Organism 0 hrs at 0 hrs days days days days A. brasiliensis 1.55 ×10⁵ 8.50 × 10⁵ ND 4.15 × 2.40 × 8.5 × 10⁴ 10⁴ 10³ C. albicans 1.05 × 10⁵1.30 × 10⁴ ND <5 <5 <5 P. aeruginosa 5.05 × 10⁵ <50 <50 <5 <5 <5 S.aureus 6.00 × 10⁵ 6.20 × 10⁵ <50 <5 <5 <5 E. coli 6.05 × 10⁵ <50 <50 <5<5 <5 M. luteus 1.65 × 10⁵ 6.50 × 10⁴ <50 <5 <5 <5 ND: not determined

TABLE 10 Full AET Challenge Test Reference Formulation: 0.0 mg/mLS-ketamine, Denatonium Benzoate (to mimic S-ketamine HCl taste), pH 5.21Blank at 0 At 14 At 28 Organism hours At 0 hours At 2 days At 7 daysdays days A. Brasileinsis 1.55 × 10⁵ 1.75 × 10⁵ — 4.35 × 10⁴ 8.00 × 10⁴9.00 × 10⁴ C. Albicans 1.05 × 10⁵ 1.20 × 10⁵ — 1.02 × 10⁵ 1.40 × 10⁵1.30 × 10⁵ P. aeruginosa 5.05 × 10⁵ 4.05 × 10⁵ 6.55 × 10⁵ >2.00 × 10⁵ 9.75 × 10⁵ 2.40 × 10⁶ S. aureus 6.00 × 10⁵ 5.15 × 10⁵ 3.90 × 10⁵ 1.55 ×10² <5 <5 E. coli 6.05 × 10⁵ 5.55 × 10⁵ 6.40 × 10⁵ >2.00 × 10⁵  8.25 ×10⁵ 1.09 × 10⁶ M. luteus 1.65 × 10⁵ 6.00 × 10⁴ 8.50 × 10⁴ 4.30 × 10²2.50 × 10³ 3.90 × 10²

As shown in Tables 5-10 above, after 28 days, all the testedformulations reduced the original spike (10⁵-10⁶ CFU/ml) of bacteria(i.e. Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coliand environmental isolate Staphylococcus haemolyticus) and environmentalMicrococcus Luteus, and also of the yeast Candida albicans. The testedformulations were not able to reduce the original spike of Aspergillusbrasiliensis to the same extent as for the bacteria and yeast, but noincrease was observed after 28 days of incubation at room temperature.

In summary, the results presented in Biological Example 1 and BiologicalExample 2 indicated that S-ketamine hydrochloride exhibits strongantimicrobial properties against Pseudomonas aeruginosa, Staphylococcusaureus, Escherichia coli, environmental isolate Staphylococcushaemolyticus, environmental Micrococcus Luteus, and the yeast Candidaalbicans. For Aspergillus brasiliensis the decrease in microorganisms isless pronounced, but no increase was observed, indicating someinhibitory activity.

EXAMPLE 3 Rat pK Penetration Studies Rat Study Procedure:

Male Sprague Dawley rats weighing around 250 g were housed individuallyin cages of 800 cm² with limited access under routine test conditions oftemperature (20° C.-24° C.), relative humidity (45%-65%) and 12/12 lightcycle. Nine male Sprague Dawley rats per formulation were tested. Theanimals were shortly anesthetized with isoflurane (2-2.5% for 5 minutes)and were then dosed intranasally. The test formulations were dosed at avolume of 10 μl/rat in a single dose. The approximate body weight of therats was 250 g, thus S-ketamine was dosed at ±6 mg/kg. Intranasal dosingwas done by placing a small pipette at the opening of the right nostril,then the compound was given and the rat was kept for another minuteunder anesthesia. Afterwards, the rat was placed back in his cage. Bloodfor pharmacokinetics was taken at 2.5, 5, 10 and 15 minutes after dosingvia the tail vein.

Formulation 3-A:

S-ketamine hydrochloride (eq. 150 mg/mL) was mixed with water and the pHof the resulting mixture adjusted with 1N NaOH to pH 4.52.

Formulations 3-B, 3-C, 3-D:

S-ketamine hydrochloride (eq. 150 mg/mL) and TUDCA (3-B:@1.25 mg/mL,3-C: @5.0 mg/mL, 3-D: @10 mg/mL) were mixed with water and the pH of theresulting mixture adjusted with 1N NaOH to pH 4.51.

Formulation 3-E:

S-ketamine hydrochloride (eq. 150 mg/mL) was mixed with water and the pHof the resulting mixture adjusted with 1N NaOH to pH 3.77.

Formulation 3-F:

S-ketamine hydrochloride (eq. 150 mg/mL) was mixed with water, thencitric acid monohydrate at 2.73 mg/ml and the pH of the resultingmixture adjusted with 1N NaOH to pH 4.45.

Formulations 3-A through 3-F were tested according to the procedure asdescribed above, with measured plasma levels of S-ketamine as listed inTable 11, below.

TABLE 11 Rat pK Study Results Plasma Level Mean ± SEM (ng/mL)Formulations 2.5 min 5 min 10 min 15 min 3-A 150 ± 24 254 ± 24 374 ± 26344 ± 29 3-B 135 ± 16 288 ± 24  379 ± 102 353 ± 37 3-C 246 ± 28 499 ± 52522 ± 47 446 ± 35 3-D 283 ± 24 474 ± 41 430 ± 32 338 ± 28 3-E 145 ± 24240 ± 24 296 ± 22 277 ± 29 3-F 144 ± 22 217 ± 20 292 ± 31 284 ± 36

EXAMPLE 4 Dog pK Penetration Studies

Beagle dogs weighing from 7 to 12 kg were used in this study. The dogswere housed separately in barriered testing rooms with limited access,and placed in individual pens under routine test conditions oftemperature (18° C.-25° C.), ventilation (10-15 cycles/hour) andillumination.

Four beagle dogs per formulation were tested, 2 males and 2 females pergroup. The test formulations were dosed at 3 mg/kg, a volume of 20 μl/kgin a single dose was given. The animals were dosed intranasally byplacing a small pipette at the opening of the right nostril. For thenext minute, the head of the dog was tilted so no fluid could run out ofthe nose or into the throat. Afterwards, the dog was placed back in hispen.

Blood for pharmacokinetics were taken at 5, 10, 15 and 30 minutes afterdosing via the jugular vein.

Formulation 4-A:

S-ketamine hydrochloride (eq. 150 mg/mL) was mixed with water and the pHof the resulting mixture adjusted with 1N NaOH to pH 4.52.

Formulation 4-B:

S-ketamine hydrochloride (eq. 150 mg/mL) and TUDCA (10 mg/mL) were mixedwith water and the pH of the resulting mixture adjusted with 1N NaOH topH 4.51.

Formulations 4-A and 4-B were tested according to the procedure asdescribed above, with measured plasma levels of S-ketamine as listed inTable 12, below.

TABLE 12 Dog pK Study Results Plasma Level Mean ± SEM (ng/mL) Time (min)Formulation 4-A Formulation 4-B 5 613 ± 206  3296 ± 1901 10 681 ± 2651728 ± 203 15 380 ± 66  10556 ± 397  30 307 ± 69  192 ± 40

EXAMPLE 5 Rat pK Study (KET-04/KET-06) Rat Study Procedure:

Male Sprague Dawley rats weighing around 250 g were housed individuallyin cages of 800 cm² with limited access under routine test conditions oftemperature (20° C.-24° C.), relative humidity (45%-65%) and 12/12 lightcycle. Nine male Sprague Dawley rats per formulation were tested. Theanimals were shortly anesthetized with isoflurane (2-2.5% for 5 minutes)and were then dosed intranasally. The test formulations were dosed at avolume of 10 μl/rat or 25 μl/rat (as noted below) in a single dose. Theapproximate body weight of the rats was 250 g, thus S-ketamine was dosedat ±6 mg/kg. Intranasal dosing was done by placing a small pipette atthe opening of the right nostril, then the compound was given and therat was kept for another minute under anesthesia. Afterwards, the ratwas placed back in his cage. Blood for pharmacokinetics was taken at2.5, 5, 10 and 15 minutes after dosing via the tail vein.

Formulation 5-A:

S-ketamine hydrochloride (eq. 150 mg/mL) was mixed with water and the pHof the resulting mixture adjusted with 1N NaOH to pH 4.5.

Formulations 5-B, 5-C, 5-D:

S-ketamine hydrochloride (eq. 150 mg/mL) and TUDCA (5-B:@5 mg/mL, 5-C:@10.0 mg/mL, 5-D: @15 mg/mL) were mixed with water and the pH of theresulting mixture adjusted with 1N NaOH to pH 4.5.

Reference Formulation 5-E:

TUDCA @ 10 mg/mL

Formulations 5-A through 5-D and reference formulation 5-E were testedaccording to the procedure as described above, with measured plasmalevels of S-ketamine (in ng/mL) as a function of time, as shown in FIGS.1, 2, and 3.

Formulations 5-A through 5-D and reference formulation 5-E were testedaccording to the procedure as described above, with measured S-ketamineand TUDCA plasma levels, as listed in Table 13, below.

TABLE 13 Rat pK Study Results Formulations 2.5 min 5 min 10 min 15 minS-Ketamine Plasma Level Mean ± SEM (ng/mL) Dosing 10 μl/rat 5-A 130 ± 12271 ± 19 367 ± 33 352 ± 37 5-B 365 ± 76 511 ± 53 525 ± 71 430 ± 60 5-C494 ± 62 681 ± 60 623 ± 65 492 ± 60 5-D 422 ± 53 588 ± 78 556 ± 72 432 ±51 S-Ketamine Plasma Level Mean ± SEM (ng/mL) Dosing 25 μl/rat 5-A  339± 109  642 ± 143  899 ± 118  797 ± 143 5-C  732 ± 246 1154 ± 304 1018 ±261  997 ± 183   TUDCA Plasma Level Mean ± SEM (ng/mL) Dosing 25 μl/rat5-C 250 ± 17 346 ± 27 303 ± 35 242 ± 32 5-E  624 ± 128 1209 ± 219  822 ±152  756 ± 118

Nasal Cavity Histopathology

Nasal cavity (respiratory epithelium) histology was visually evaluatedand scored for tissue damage, including but not limited to degenerationand detachment, as follows: 1=minimal, 2=slight, 3=moderate, 4=marked,532 severe/massive.

Respiratory epithelium from rats treated with Formulations 5-A through5-D at 1 μL/rat and rats treated with Formulation 5-A, 5-C and referenceformulation 5-E at 25 μL/rat were evaluated and scored as describedabove, with results as listed in Table 14, below.

TABLE 14 Nasal cavity (Respiratory Epithelium) HistopathologyFormulations dosed @ 10 μl/rat 5-A Minimal degeneration of respiratoryepithelium; No tissue change 5-B Slight to moderate degeneration ofrespiratory epithelium, and 5-C with/without detachment of respiratoryepithelium 5-D Slight degeneration of respiratory epithelium, withdetachment of respiratory epithelium Formulations dosed at 25 μl/rat 5-ASlight degeneration of respiratory epithelium; Slightly more severe thanminimal scope 5-C Minimal to moderate degeneration of respiratoryepithelium; More variable than Formulation 5-A 5-E No degeneration(Ref.)

While the foregoing specification teaches the principles of the presentinvention, with examples provided for the purpose of illustration, itwill be understood that the practice of the invention encompasses all ofthe usual variations, adaptations and/or modifications as come withinthe scope of the following claims and their equivalents.

We claim:
 1. A pharmaceutical composition comprising S-ketaminehydrochloride and water; wherein the pharmaceutical composition does notcontain an antimicrobial preservative.
 2. The pharmaceutical compositionaccording to claim 1, which (i) additionally contains a buffer; and/or(ii) has a pH value within the range of from 4.0 to 6.5.
 3. Thepharmaceutical composition according to claim 1, wherein the S-ketaminehydrochloride is present in a concentration in the range of eq. 100mg/mL to eq. 200 mg/mL, based on the total volume of the composition. 4.The pharmaceutical composition according to claim 1, wherein theS-ketamine hydrochloride is present in a concentration in the range ofeq. 125 mg/mL to eq. 150 mg/mL, based on the total volume of thecomposition.
 5. The pharmaceutical composition according to claim 1,wherein the S-ketamine hydrochloride is present in a concentration inthe range of 126 mg/mL to 162 mg/mL, based on the total volume of thecomposition.
 6. The pharmaceutical composition according to claim 1,wherein the pharmaceutical composition is formulated for nasaladministration.
 7. The pharmaceutical composition according to claim 2,wherein the pharmaceutical composition further contains a buffer.
 8. Thepharmaceutical composition according to claim 6, wherein the buffer is1N NaOH.
 9. The pharmaceutical composition according to claim 6, whereinthe buffer is present in an amount sufficient to adjust the pH of thepharmaceutical composition to a pH in the range of from pH 3.5 to pH6.5.
 10. The pharmaceutical composition according to claim 6, whereinthe buffer is present in an amount sufficient to adjust the pH of thecomposition to a pH in the range of from pH 4.5 to pH 5.5.
 11. Thepharmaceutical composition according to claim 1, wherein thepharmaceutical composition exhibits a shelf-life under acceleratedstorage conditions of at least 3 months.
 12. The pharmaceuticalcomposition according to claim 1; wherein the pharmaceutical compositionfurther contains a penetrating agent.
 13. The pharmaceutical compositionaccording to claim 11; wherein the penetrating agent istauroursodeoxycholic acid.
 14. The pharmaceutical composition accordingto claim 1; wherein the pharmaceutical composition further containstauroursodeoxycholic acid in a concentration in the range of from 1mg/mL to 25 mg/mL, based on the total volume of the composition.
 15. Thepharmaceutical composition according to claim 2; wherein thepharmaceutical composition further contains tauroursodeoxycholic acid ina concentration in the range of from 5 mg/mL to 10 mg/mL.
 16. Apharmaceutical dosage form comprising the pharmaceutical compositionaccording to any of claims
 1. 17. The dosage form according to claim 15,which is adapted for nasal administration.
 18. The pharmaceuticalcomposition according to claim 1 or the pharmaceutical dosage formaccording to claim 16 for use in the treatment of depression.
 19. Thepharmaceutical composition or the pharmaceutical dosage form accordingto claim 18, wherein the depression is selected from the groupconsisting of major depressive disorder, unipolar depression,treatment-refractory depression, resistant depression, anxiousdepression and bipolar depression.
 20. The pharmaceutical composition orthe pharmaceutical dosage form according to claim 18, wherein thedepression is selected from the group consisting of resistant depressionor treatment refractory depression.
 21. A pharmaceutical compositioncomprising S-ketamine hydrochloride as herein described.
 22. A dosageform comprising a pharmaceutical composition as herein described.
 23. Amethod of treating any disorder herein described comprisingadministration of a therapeutically effective amount of a pharmaceuticalcomposition as herein described.